{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T21:21:36Z","timestamp":1778361696030,"version":"3.51.4"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T00:00:00Z","timestamp":1601078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"British Heart Foundation Centre of Research Excellence Award"},{"DOI":"10.13039\/501100000274","name":"BHF","doi-asserted-by":"publisher","award":["RE\/18\/6\/34217"],"award-info":[{"award-number":["RE\/18\/6\/34217"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,1]]},"DOI":"10.1093\/cvr\/cvaa247","type":"journal-article","created":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T19:28:18Z","timestamp":1596828498000},"page":"e152-e155","source":"Crossref","is-referenced-by-count":13,"title":["Vericiguat in worsening heart failure: agonising over, or celebrating, agonism in the VICTORIA trial"],"prefix":"10.1093","volume":"116","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8441-6887","authenticated-orcid":false,"given":"Ninian N","family":"Lang","sequence":"first","affiliation":[{"name":"BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, 126 University Place, Glasgow G12 8TA, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9111-0242","authenticated-orcid":false,"given":"Stephen J H","family":"Dobbin","sequence":"additional","affiliation":[{"name":"BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, 126 University Place, Glasgow G12 8TA, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark C","family":"Petrie","sequence":"additional","affiliation":[{"name":"BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, 126 University Place, Glasgow G12 8TA, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,9,26]]},"reference":[{"key":"2020092620145632600_cvaa247-B1","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2020092620145632600_cvaa247-B2","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"New Engl J Med"},{"key":"2020092620145632600_cvaa247-B3","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2020092620145632600_cvaa247-B4","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"2020092620145632600_cvaa247-B5","first-page":"1883","article-title":"Comparing the benefit of novel therapies across clinical trials: insights from the VICTORIA trial","volume":"382","author":"Butler","year":"2020","journal-title":"Circulation"},{"key":"2020092620145632600_cvaa247-B6","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"2020092620145632600_cvaa247-B7","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1161\/CIRCULATIONAHA.110.981738","article-title":"Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease","volume":"123","author":"Stasch","year":"2011","journal-title":"Circulation"},{"key":"2020092620145632600_cvaa247-B8","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11897-018-0383-y","article-title":"Multiple avenues of modulating the nitric oxide pathway in heart failure clinical trials","volume":"15","author":"Singh","year":"2018","journal-title":"Curr Heart Fail Rep"},{"key":"2020092620145632600_cvaa247-B9","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1056\/NEJMoa042934","article-title":"Combination of isosorbide dinitrate and hydralazine in blacks with heart failure","volume":"351","author":"Taylor","year":"2004","journal-title":"N Engl J Med"},{"key":"2020092620145632600_cvaa247-B10","doi-asserted-by":"crossref","first-page":"5146","DOI":"10.1021\/acs.jmedchem.7b00449","article-title":"Discovery of the soluble guanylate cyclase stimulator vericiguat (BAY 1021189) for the treatment of chronic heart failure","volume":"60","author":"Follmann","year":"2017","journal-title":"J Med Chem"},{"key":"2020092620145632600_cvaa247-B11","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10741-009-9149-7","article-title":"Role of guanylate cyclase modulators in decompensated heart failure","volume":"14","author":"Mitrovic","year":"2009","journal-title":"Heart Fail Rev"},{"key":"2020092620145632600_cvaa247-B12","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jchf.2017.08.013","article-title":"A multicenter, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral soluble guanylate cyclase stimulator: the VICTORIA trial","volume":"6","author":"Armstrong","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2020092620145632600_cvaa247-B13","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00210-019-01779-z","article-title":"cGMP: a unique 2nd messenger molecule\u2014recent developments in cGMP research and development","volume":"393","author":"Friebe","year":"2020","journal-title":"Naunyn-Schmied Arch Pharmacol"}],"container-title":["Cardiovascular Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cardiovascres\/article-pdf\/116\/12\/e152\/33796028\/cvaa247.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cardiovascres\/article-pdf\/116\/12\/e152\/33796028\/cvaa247.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T00:15:37Z","timestamp":1601165737000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article\/116\/12\/e152\/5912060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,26]]},"references-count":13,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,9,26]]},"published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cvr\/cvaa247","relation":{},"ISSN":["0008-6363","1755-3245"],"issn-type":[{"value":"0008-6363","type":"print"},{"value":"1755-3245","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,10,1]]},"published":{"date-parts":[[2020,9,26]]}}}